학술논문
Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand
Document Type
article
Author
Nicolas Salvadori; Gonzague Jourdain; Rungroj Krittayaphong; Taweegrit Siripongboonsitti; Subsai Kongsaengdao; Kriangsak Atipornwanich; Parichart Sakulkonkij; Nasikarn Angkasekwinai; Rujipas Sirijatuphat; Sarunyou Chusri; Tanavit Mekavuthikul; Anucha Apisarnthanarak; Sirawat Srichatrapimuk; Somnuek Sungkanuparph; Suppachok Kirdlarp; Thanyakamol Phongnarudech; Suraphan Sangsawang; Panuwat Napinkul; Jullapong Achalapong; Suwimon Khusuwan; Piyanut Pratipanawat; Pornboonya Nookeu; Namphol Danpipat; Pornvimol Leethong; Piya Hanvoravongchai; Pra-ornsuda Sukrakanchana; Prasert Auewarakul
Source
International Journal of Infectious Diseases, Vol 143, Iss , Pp 107021- (2024)
Subject
Language
English
ISSN
1201-9712
Abstract
Objectives: Evaluate and compare the efficacy and safety of molnupiravir and favipiravir in outpatients with mild to moderate COVID-19 and at risk of severe COVID-19. Methods: In an open-label, parallel-group, multicenter trial in Thailand, participants with moderate COVID-19 and at least one factor associated with severe COVID-19 were randomly assigned 1:1 to receive oral molnupiravir or oral favipiravir (standard of care). Phone calls for remote symptom assessment were made on Days 6, 15, and 29. Participants with worsening symptoms were instructed to return to the hospital. The primary endpoint was pulmonary involvement by Day 29, as evidenced by ≥2 of the following: dyspnea, oxygen saturation